Drug utilization of clarithromycin for gastrointestinal disease treatment

World Journal of Gastroenterology

Volumn 14, Issue 39, 2008, Pages 6065-6071

  Zhou, Quan ^a   Zhu, Ling Ling ^a   Yan, Xiao Feng ^a   Pan, Wen Sheng ^a   Zeng, Su ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Clarithromycin; Drug administration schedule; Drug interactions; Drug utilization; Gastrointestinal diseases; Helicobacter pylori; Polypharmacy; Polypharmacyinteractions; Prescriptions

Indexed keywords

ALPRAZOLAM; AMLODIPINE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ATORVASTATIN; BIAXIN XL FILMTAB; BISMUTH; CARBAMAZEPINE; CLARITHROMYCIN; CLOPIDOGREL; CYTOCHROME P450 3A; DIHYDROERGOTOXINE; ESOMEPRAZOLE; FURAZOLIDONE; KLACI; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MIDAZOLAM; NIFEDIPINE; NUOBANG; OMEPRAZOLE; PANTOPRAZOLE; PREDNISONE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE BISMUTH CITRATE; TINIDAZOLE; UNCLASSIFIED DRUG; ZOLPIDEM; ANTIINFECTIVE AGENT; PROTEIN SYNTHESIS INHIBITOR;

ADULT; AGED; ARTICLE; CHRONIC GASTRITIS; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG USE; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; OFF LABEL DRUG USE; OUTPATIENT CARE; PEPTIC ULCER; PRESCRIPTION; SUSTAINED RELEASE FORMULATION; ADOLESCENT; CHINA; DOSE RESPONSE; DRUG COMBINATION; DRUG INTERACTION; GENERAL HOSPITAL; MEDICAL AUDIT; MIDDLE AGED; OUTPATIENT; POSTPRANDIAL STATE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHINA; CLARITHROMYCIN; CLINICAL AUDIT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; FEMALE; GASTROINTESTINAL DISEASES; HELICOBACTER INFECTIONS; HOSPITALS, GENERAL; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; POSTPRANDIAL PERIOD; PROTEIN SYNTHESIS INHIBITORS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 59849109735     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.6065     Document Type: Article

References (38)

1. Alberta Medical Association. Guideline for treatment of Helicobacter Pylori infection in adults, 2007. Available from: URL: http://www.topalbertadoctors.org/cpgs/hpylori.html
2. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-1825
3. Gotfried M, Notario G, Spiller J, Palmer R, Busman T. Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis. Curr Med Res Opin 2005; 21: 245-254
4. Guay DR, Gustavson LE, Devcich KJ, Zhang J, Cao G, Olson CA. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin Ther 2001; 23: 566-577
5. Zhou Q,, Yan XF, Zhang ZM, Pan WS, Zeng S. Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions. World J Gastroenterol 2007; 13: 5618-5628
6. Abbott Laboratories, USA. BIAXIN® prescribing information, 2005. Available from: URL: http://www.fda.gov/medwatch/SAFETY/2005/ Oct_PI/Biaxin_PI.pdf
7. A.D.A.M., Inc. Zolpidem information. Available from: URL: http://www.umm.edu/altmed/drugs/zolpidem-135400.htm
8. Quinney SK, Haehner BD, Rhoades MB, Lin Z, Gorski JC, Hall SD. Interaction between midazolam and clarithromycin in the elderly. Br J Clin Pharmacol 2008; 65: 98-109
9. A.D.A.M., Inc. Amlodipine information. Available from: URL: http://www.umm.edu/altmed/drugs/amlodipine-005950.htm
10. Gerónimo-Pardo M, Cuartero-del-Pozo AB, Jiménez-Vizuete JM, Cortiñas-Sáez M, Peyró-García R. Clarithromycin-nifedipine interaction as possible cause of vasodilatory shock. Ann Pharmacother 2005; 39: 538-542
11. Metz DC, Getz HD. Helicobacter pylori gastritis therapy with omeprazole and clarithromycin increases serum carbamazepine levels. Dig Dis Sci 1995; 40: 912-915
12. Amsden GW, Kuye O, Wei GC. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol 2002; 42: 444-449
13. Sipe BE, Jones RJ, Bokhart GH. Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction. Ann Pharmacother 2003; 37: 808-811
14. A.D.A.M., Inc. Clopidogrel information. Available from: URL: http://www.umm.edu/altmed/drugs/clopidogrel-030450.htm
15. A.D.A.M., Inc. Ergoloid mesylates information. Available from: URL: http://www.umm.edu/altmed/drugs/ergoloid-mesylates-048700.htm
16. Finkenbine RD, Frye MD. Case of psychosis due to prednisone-clarithromycin interaction. Gen Hosp Psychiatry 1998; 20: 325-326
17. Tao RH. Association of mycoplasma infection with clinical efficacy in 108 patients with mesenteric lymphadenitis. Jiangxi Yiyao 2007; 42: 440-441
18. Coelho LG, Martins GM, Passos MC, Bueno ML, Sanches BS, Lopes LG, Miranda CH, Castro LP. Once-daily, lowcost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients. Aliment Pharmacol Ther 2003; 17: 131-136
19. Chu KM, Kwok KF, Law SY, Wong J. One-week oncedaily triple therapy for Helicobacter pylori - a pilot study. Hepatogastroenterology 2000; 47: 1624-1626
20. Liou JM, Chen CY, Wu MS, Hsu MT, Fang CC, Lin YL, Chang MC, Lin JT, Wang HP. Comparative study of modified-release clarithromycin and immediate-release clarithromycin in the treatment of Helicobacter pylori-associated peptic ulcer disease. Hepatogastroenterology 2006; 53: 792-796
21. Gustavson LE, Kaiser JF, Edmonds AL, Locke CS, DeBartolo ML, Schneck DW. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995; 39: 2078-2083
22. Mainz D, Borner K, Koeppe P, Kotwas J, Lode H. Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. J Antimicrob Chemother 2002; 50: 699-706
23. AstraZeneca, USA. NEXIUM prescribing information, 2006. Available from: URL: http://www.fda.gov/cder/foi/label/2006/021153s022lbl.pdf
24. RxList Inc. Aciphex information. Available from: URL: http://www.rxlist.com/cgi/generic/aciphex.htm
25. Calabresi L, Pazzucconi F, Ferrara S, Di Paolo A, Tacca MD, Sirtori C. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. Pharmacol Res 2004; 49: 493-499
26. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-37
27. Cianci R, Montalto M, Pandolfi F, Gasbarrini GB, Cammarota G. Third-line rescue therapy for Helicobacter pylori infection. World J Gastroenterol 2006; 12: 2313-2319
28. Guo CY, Wu YB, Liu HL, Wu JY, Zhong MZ. Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection. World J Gastroenterol 2004; 10: 747-749
29. Kumala W, Rani A. Patterns of Helicobacter pylori isolate resistance to fluoroquinolones, amoxicillin, clarithromycin and metronidazoles. Southeast Asian J Trop Med Public Health 2006; 37: 970-974
30. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-180
31. Shi JM, Li WP. Analysis of the antibiotic resistance rate of Helicobacter Pylori. Yixue Yanjiu Zazhi 2007; 36: 98-100
32. Dai N, Zhou G, Yan J. [Correlation of rdxA gene mutation and metronidazole resistance of Helicobacter pylori] Zhejiangdaxue Xuebao Yixueban 2003; 32: 37-40
33. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-1384
34. Tanaka M, Isogai E, Isogai H, Hayashi S, Hirose K, Kimura K, Sugiyama T, Sato K. Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori. J Antimicrob Chemother 2002; 49: 1039-1040
35. Kwon DH, Lee M, Kim JJ, Kim JG, El-Zaatari FA, Osato MS, Graham DY. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance. Antimicrob Agents Chemother 2001; 45: 306-308
36. Bardhan KD, Dallaire C, Eisold H, Duggan AE. Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal ulcer. Gut 1997; 41: 181-186
37. Buzás GM, Józan J. First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2004. World J Gastroenterol 2006; 12: 5311-5319
38. Mesquita MA, Lorena SL, Almeida JR, Montes CG, Guerrazzi F, Campos LT, Zeitune JM. One-week dual therapy with ranitidine bismuth citrate and clarithromycin for the treatment of Helicobacter pylori infection in Brazilian patients with peptic ulcer. World J Gastroenterol 2005; 11: 3566-3569